Xenon and Genentech Ink Rx, Companion Dx Collaboration and License Pact | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Canadian drug discovery firm Xenon said this week that it will collaborate with Genentech to discover and develop compounds and companion diagnostics for treating pain.

The pact could bring Burnaby, BC-based Xenon up to $646 million in total payments.

The agreement gives Genentech a non-exclusive license to develop and commercialize diagnostics developed under the collaboration and an exclusive license to compounds, Xenon said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.